Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
Identifieur interne : 004401 ( Ncbi/Merge ); précédent : 004400; suivant : 004402Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
Auteurs : Joaquim J. Ferreira [Portugal] ; Anne Rosser [Royaume-Uni] ; David Craufurd [Royaume-Uni] ; Ferdinando Squitieri [Italie] ; Nicholas Mallard [États-Unis] ; Bernhard Landwehrmeyer [Allemagne]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.
Abstract
It has been suggested that treatment with ethyl-eicosapentaenoic acid (EPA) may improve motor function in patients with Huntington's disease (HD) with cytosine-adenine-guanine repeat numbers of <45.
DOI: 10.1002/mds.26308
PubMed: 26175332
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000117
- to stream PubMed, to step Curation: 000117
- to stream PubMed, to step Checkpoint: 000243
Links to Exploration step
pubmed:26175332Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.</title><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J" last="Ferreira">Joaquim J. Ferreira</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon</wicri:regionArea><wicri:noRegion>University of Lisbon</wicri:noRegion></affiliation></author><author><name sortKey="Rosser, Anne" sort="Rosser, Anne" uniqKey="Rosser A" first="Anne" last="Rosser">Anne Rosser</name><affiliation wicri:level="1"><nlm:affiliation>Cardiff Schools of Medicine and Biosciences, Cardiff University, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cardiff Schools of Medicine and Biosciences, Cardiff University</wicri:regionArea><wicri:noRegion>Cardiff University</wicri:noRegion></affiliation></author><author><name sortKey="Craufurd, David" sort="Craufurd, David" uniqKey="Craufurd D" first="David" last="Craufurd">David Craufurd</name><affiliation wicri:level="4"><nlm:affiliation>University of Manchester, Manchester Academic Health Sciences Center and Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Manchester, Manchester Academic Health Sciences Center and Central Manchester University Hospitals NHS Foundation Trust, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author><author><name sortKey="Squitieri, Ferdinando" sort="Squitieri, Ferdinando" uniqKey="Squitieri F" first="Ferdinando" last="Squitieri">Ferdinando Squitieri</name><affiliation wicri:level="1"><nlm:affiliation>IRCSS Neuromed, Pozzilli, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>IRCSS Neuromed, Pozzilli</wicri:regionArea><wicri:noRegion>Pozzilli</wicri:noRegion></affiliation></author><author><name sortKey="Mallard, Nicholas" sort="Mallard, Nicholas" uniqKey="Mallard N" first="Nicholas" last="Mallard">Nicholas Mallard</name><affiliation wicri:level="2"><nlm:affiliation>Amarin Pharma Inc., Bedminster, New Jersey, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amarin Pharma Inc., Bedminster, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Landwehrmeyer, Bernhard" sort="Landwehrmeyer, Bernhard" uniqKey="Landwehrmeyer B" first="Bernhard" last="Landwehrmeyer">Bernhard Landwehrmeyer</name><affiliation wicri:level="3"><nlm:affiliation>Universitätsklinik Ulm, Ulm, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Universitätsklinik Ulm, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26175332</idno><idno type="pmid">26175332</idno><idno type="doi">10.1002/mds.26308</idno><idno type="wicri:Area/PubMed/Corpus">000117</idno><idno type="wicri:Area/PubMed/Curation">000117</idno><idno type="wicri:Area/PubMed/Checkpoint">000243</idno><idno type="wicri:Area/Ncbi/Merge">004401</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.</title><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J" last="Ferreira">Joaquim J. Ferreira</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon</wicri:regionArea><wicri:noRegion>University of Lisbon</wicri:noRegion></affiliation></author><author><name sortKey="Rosser, Anne" sort="Rosser, Anne" uniqKey="Rosser A" first="Anne" last="Rosser">Anne Rosser</name><affiliation wicri:level="1"><nlm:affiliation>Cardiff Schools of Medicine and Biosciences, Cardiff University, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cardiff Schools of Medicine and Biosciences, Cardiff University</wicri:regionArea><wicri:noRegion>Cardiff University</wicri:noRegion></affiliation></author><author><name sortKey="Craufurd, David" sort="Craufurd, David" uniqKey="Craufurd D" first="David" last="Craufurd">David Craufurd</name><affiliation wicri:level="4"><nlm:affiliation>University of Manchester, Manchester Academic Health Sciences Center and Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Manchester, Manchester Academic Health Sciences Center and Central Manchester University Hospitals NHS Foundation Trust, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author><author><name sortKey="Squitieri, Ferdinando" sort="Squitieri, Ferdinando" uniqKey="Squitieri F" first="Ferdinando" last="Squitieri">Ferdinando Squitieri</name><affiliation wicri:level="1"><nlm:affiliation>IRCSS Neuromed, Pozzilli, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>IRCSS Neuromed, Pozzilli</wicri:regionArea><wicri:noRegion>Pozzilli</wicri:noRegion></affiliation></author><author><name sortKey="Mallard, Nicholas" sort="Mallard, Nicholas" uniqKey="Mallard N" first="Nicholas" last="Mallard">Nicholas Mallard</name><affiliation wicri:level="2"><nlm:affiliation>Amarin Pharma Inc., Bedminster, New Jersey, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amarin Pharma Inc., Bedminster, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Landwehrmeyer, Bernhard" sort="Landwehrmeyer, Bernhard" uniqKey="Landwehrmeyer B" first="Bernhard" last="Landwehrmeyer">Bernhard Landwehrmeyer</name><affiliation wicri:level="3"><nlm:affiliation>Universitätsklinik Ulm, Ulm, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Universitätsklinik Ulm, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement></placeName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">It has been suggested that treatment with ethyl-eicosapentaenoic acid (EPA) may improve motor function in patients with Huntington's disease (HD) with cytosine-adenine-guanine repeat numbers of <45.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="In-Process"><PMID Version="1">26175332</PMID><DateCreated><Year>2015</Year><Month>09</Month><Day>03</Day></DateCreated><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>10</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.</ArticleTitle><Pagination><MedlinePgn>1426-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26308</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">It has been suggested that treatment with ethyl-eicosapentaenoic acid (EPA) may improve motor function in patients with Huntington's disease (HD) with cytosine-adenine-guanine repeat numbers of <45.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This multicenter, randomized, double-blind, placebo-controlled 6-month trial compared the effects of ethyl-EPA versus placebo on 290 subjects with mild-to-moderate HD. The primary endpoint was the change from baseline to 6 months in the Total Motor Score 4 (TMS-4) component of the Unified Huntington's Disease Rating Scale (UHDRS). Secondary endpoints included change from baseline in UHDRS subscores and Clinical Global Impression (CGI).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant differences in TMS-4 scores were noted between treatment groups. Similarly, there were no significant differences between groups on any of the UHDRS subscores or CGI scores.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Ethyl-EPA was not beneficial in patients with HD during 6 months of placebo-controlled evaluation.</AbstractText><CopyrightInformation>© 2015 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Joaquim J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosser</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiff Schools of Medicine and Biosciences, Cardiff University, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craufurd</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Manchester, Manchester Academic Health Sciences Center and Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Squitieri</LastName><ForeName>Ferdinando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IRCSS Neuromed, Pozzilli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallard</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Amarin Pharma Inc., Bedminster, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landwehrmeyer</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Universitätsklinik Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Huntington's disease</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">eicosapentaenoic acid</Keyword><Keyword MajorTopicYN="N">ethyl-EPA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2015</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26175332</ArticleId><ArticleId IdType="doi">10.1002/mds.26308</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Italie</li><li>Portugal</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Bade-Wurtemberg</li><li>District de Tübingen</li><li>Grand Manchester</li><li>New Jersey</li></region><settlement><li>Manchester</li><li>Ulm</li></settlement><orgName><li>Université de Manchester</li></orgName></list><tree><country name="Portugal"><noRegion><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J" last="Ferreira">Joaquim J. Ferreira</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Rosser, Anne" sort="Rosser, Anne" uniqKey="Rosser A" first="Anne" last="Rosser">Anne Rosser</name></noRegion><name sortKey="Craufurd, David" sort="Craufurd, David" uniqKey="Craufurd D" first="David" last="Craufurd">David Craufurd</name></country><country name="Italie"><noRegion><name sortKey="Squitieri, Ferdinando" sort="Squitieri, Ferdinando" uniqKey="Squitieri F" first="Ferdinando" last="Squitieri">Ferdinando Squitieri</name></noRegion></country><country name="États-Unis"><region name="New Jersey"><name sortKey="Mallard, Nicholas" sort="Mallard, Nicholas" uniqKey="Mallard N" first="Nicholas" last="Mallard">Nicholas Mallard</name></region></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Landwehrmeyer, Bernhard" sort="Landwehrmeyer, Bernhard" uniqKey="Landwehrmeyer B" first="Bernhard" last="Landwehrmeyer">Bernhard Landwehrmeyer</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004401 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004401 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:26175332
|texte= Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:26175332" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |